Lastly, the panel of ADMCI aAB biomarkers demonstrated exceptional agreement with the A/T/N classification system for CSF biomarkers (Aβ42/40, t-tau and p-tau) by successfully identifying 13/14 cognitively normal HFR patients (CDR = 0) as MCI, that had A/T/N designations consistent with preclinical AD. Here, MAPT is linked to Alzheimer disease.